StockNews.AI
UNCY
StockNews.AI
10 hrs

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

1. A class action lawsuit has been filed against Unicycive Therapeutics. 2. The lawsuit alleges misleading statements regarding FDA compliance and approval chances. 3. Investors can join the lawsuit if they suffered losses within a specified period. 4. The company’s public statements were deemed materially misleading. 5. The class has not been certified yet, impacting investor representation.

7m saved
Insight
Article

FAQ

Why Very Bearish?

The lawsuit highlights significant credibility issues that could deter investors, similar to past cases like Valeant Pharmaceuticals, which faced a downturn due to allegations of misleading statements.

How important is it?

Legal issues can drastically influence a stock’s price, particularly negatively, in the short term, as seen with other biotech firms facing litigation.

Why Short Term?

Immediate investor reactions to lawsuits typically lead to stock price drops, affecting sentiment and trading behavior shortly after the news breakout.

Related Companies

VNDARLXPTGX

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between March 29, 2024 and June 27, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before October 14, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Unicycive overstated its ability to satisfy FDA manufacturing compliance requirements. The Company overstated the chances of FDA approval for OLC, its treatment for hyperphosphatemia in CKD patients on dialysis. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Unicycive, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm

Brian Schall, Esq.

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

Related News